Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease

Pulmonary Pharmacology and Therapeutics

Volumn 36, Issue , 2016, Pages 46-52

  Witt, Leah J ^a   Demchuk, Carley ^b   Curran, James J ^a   Strek, Mary E ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Autoimmune disease; Idiopathic inflammatory myopathies; Immunosuppression; Interstitial lung disease

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; MYCOPHENOLATE MOFETIL; PREDNISONE; TACROLIMUS; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADULT; AGED; ALLERGIC REACTION; ARTHRALGIA; ARTICLE; BRONCHIECTASIS; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HERPES ZOSTER; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOXEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LUNG BIOPSY; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; MIDDLE AGED; NAUSEA AND VOMITING; ORGANIZING PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; SINUSITIS; TOTAL LUNG CAPACITY; TREATMENT DURATION; TREATMENT OUTCOME; CASE REPORT; COMBINATION DRUG THERAPY; CONNECTIVE TISSUE DISEASES; DERMATOMYOSITIS; DIAGNOSTIC IMAGING; LUNG DISEASES, INTERSTITIAL; PATHOPHYSIOLOGY; PHYSIOLOGIC MONITORING; RADIOGRAPHY; RETROSPECTIVE STUDY; VITAL CAPACITY;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CONNECTIVE TISSUE DISEASES; DERMATOMYOSITIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; RADIOGRAPHY; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; TACROLIMUS; TOTAL LUNG CAPACITY; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84957702993     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2015.12.004     Document Type: Article

References (37)

1. Vij R., Strek M.E. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. CHEST J. 2013, 143:814-824.
2. Fischer A., du Bois R. Interstitial lung disease in connective tissue disorders. Lancet 2012, 380:689-698.
3. Connors G.R., Christopher-Stine L., Oddis C.V., Danoff S.K. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?. Chest 2010, 138:1464-1474.
4. Marie I., Hachulla E., Cherin P., Dominique S., Hatron P.Y., Hellot M.F., Devulder B., Herson S., Levesque H., Courtois H. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Care & Res. 2002, 47:614-622.
5. Cottin V., Thivolet-Bejui F., Reynaud-Gaubert M., Cadranel J., Delaval P., Ternamian P.J., Cordier J.F. Groupe d'Etudes et de Recherche sur les Maladies Orphelines P. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur. Respir. J. Official J. Eur. Soc. Clin. Respir. Physiol. 2003, 22:245-250.
6. Marguerie C., Bunn C.C., Beynon H.L.C., Bernstein R.M., Hughes J.M.B., So A.K., Walport M.J. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-trna synthetase enzymes. QJM 1990, 77:1019-1038.
7. Kinder B.W., Collard H.R., Koth L., Daikh D.I., Wolters P.J., Elicker B., Jones K.D., King T.E. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?. Am. J. Respir. Crit. Care Med. 2007, 176:691-697.
8. Oddis C.V. Idiopathic inflammatory myopathies: A treatment update. Curr. Rheumatol. Rep. 2003, 5:431-436.
9. Mira-Avendano I.C., Parambil J.G., Yadav R., Arrossi V., Xu M., Chapman J.T., Culver D.A. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir. Med. 2013, 107:890-896.
10. Koreeda Y., Higashimoto I., Yamamoto M., Takahashi M., Kaji K., Fujimoto M., Kuwana M., Fukuda Y. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-trna synthetase autoantibodies. Intern. Med. 2010, 49:361-369.
11. Marie I., Josse S., Hatron P., Dominique S., Hachulla E., Janvresse A., Cherin P., Mouthon L., Vittecoq O., Menard J.F. Interstitial lung disease in anti-jo-1 patients with antisynthetase syndrome. Arthritis care & Res. 2013, 65:800-808.
12. Späth M., Schröder M., Schlotter-Weigel B., Walter M.C., Hautmann H., Leinsinger G., Pongratz D., Müller-Felber W. The long-term outcome of anti-jo-1-positive inflammatory myopathies. J. Neurol. 2004, 251:859-864.
13. Marie I., Hachulla E., Cherin P., Dominique S., Hatron P.Y., Hellot M.F., Devulder B., Herson S., Levesque H., Courtois H. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis rheumatism 2002, 47:614-622.
14. Matsushita T., Hasegawa M., Fujimoto M., Hamaguchi Y., Komura K., Hirano T., Horikawa M., Kondo M., Orito H., Kaji K. Clinical evaluation of anti-aminoacyl trna synthetase antibodies in japanese patients with dermatomyositis. J. Rheumatol. 2007, 34:1012-1018.
15. Takada K., Nagasaka K., Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: A new therapeutic approach with t-cell-specific immunosuppressants. Autoimmunity 2005, 38:383-392.
16. Oddis C.V., Sciurba F.C., Elmagd K.A., Starzl T.E. Tacrolimus in refractory poly myositis with inter stitial lung disease. Lancet 1999, 353:1762-1763.
17. Thomson A., Bonham C., Zeevi A. Mode of action of tacrolimus (fk506): molecular and cellular mechanisms. Ther. drug Monit. 1995, 17:584-591.
18. Randomised trial comparing tacrolimus (fk506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994, 344:423-428.
19. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: A randomised multicentre study. Lancet 2002, 359:741-746.
20. Krämer B.K., Montagnino G., del Castillo D., Margreiter R., Sperschneider H., Olbricht C.J., Krüger B., Ortuño J., Köhler H., Kunzendorf U., Stummvoll H.-K., Tabernero J.M., Mühlbacher F., Rivero M., Arias M. Group ftETvCMRTS. Efficacy and safety of tacrolimus compared with cyclosporin a microemulsion in renal transplantation: 2 year follow-up results. Nephrol. Dial. Transplant. 2005, 20:968-973.
21. Halloran P.F. Immunosuppressive drugs for kidney transplantation. N. Engl. J. Med. 2004, 351:2715-2729.
22. Böttiger Y., Brattström C., Tyden G., Säwe J., Groth C. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br. J. Clin. Pharmacol. 1999, 48:445.
23. Ochi S., Nanki T., Takada K., Suzuki F., Komano Y., Kubota T., Miyasaka N. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin. Exp. Rheumatol. 2005, 23:707.
24. Wilkes M.R., Sereika S.M., Fertig N., Lucas M.R., Oddis C.V. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis rheumatism 2005, 52:2439-2446.
25. Ando M., Miyazaki E., Yamasue M., Sadamura Y., Ishii T., Takenaka R., Ito T., Nureki S., Kumamoto T. Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin. Rheumatol. 2010, 29:443.
26. Guglielmi S., Merz T.M., Gugger M., Suter C., Nicod L.P. Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus. Eur. Respir. J. official J. Eur. Soc. Clin. Respir. Physiol. 2008, 31:213-217.
27. Kurita T., Yasuda S., Oba K., Odani T., Kono M., Otomo K., Fujieda Y., Oku K., Bohgaki T., Amengual O., Horita T., Atsumi T. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology 2015, 54(1):39-44.
28. Meyer K.C., Bierach J. Immunosuppressive therapy for autoimmune lung diseases. Immunol. allergy Clin. N. Am. 2012, 32:633-669.
29. Witt L., Demchuk C., Curran J., Strek M. Safety and efficacy of tacrolimus in connective tissue disease-related interstitial lung disease. CHEST J. 2013, 144. 470A-470A.
30. Curran J., Strek M., Witt L. Successful treatment of dermatomyositis-related interstitial lung disease with tacrolimus plus azathioprine. Am. J. Respir. Crit. Care Med. 2013, 187:A5776.
31. Baughman R.P., Meyer K.C., Nathanson I., Angel L., Bhorade S.M., Chan K.M., Culver D., Harrod C.G., Hayney M.S., Highland K.B., Limper A.H., Patrick H., Strange C., Whelan T. Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American college of chest physicians evidence-based clinical practice guidelines. CHEST J. 2012, 142:e1S-e111S.
32. Vananuvat P., Suwannalai P., Sungkanuparph S., Limsuwan T., Ngamjanyaporn P., Janwityanujit S. Primary Prophylaxis for Pneumocystis Jirovecii Pneumonia in Patients with Connective Tissue Diseases. Seminars in Arthritis and Rheumatism 2011, 497-502. Elsevier.
33. Christians U., Jacobsen W., Benet L.Z., Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin. Pharmacokinet. 2002, 41:813-851.
34. Douglas W.W., Tazelaar H.D., Hartman T.E., Hartman R.P., Decker P.A., Schroeder D.R., Ryu J.H. Polymyositis-dermatomyositis-associated interstitial lung disease. Am. J. Respir. Crit. care Med. 2001, 164:1182-1185.
35. Matsubara S., Kondo K., Sugaya K., Miyamoto K. Effects of tacrolimus on dermatomyositis and polymyositis: A prospective, open, non-randomized study of nine patients and a review of the literature. Clin. Rheumatol. 2012.
36. Keir G.J., Maher T.M., Hansell D.M., Denton C.P., Ong V.H., Singh S., Wells A.U., Renzoni E.A. Severe interstitial lung disease in connective tissue disease: Rituximab as rescue therapy. Eur. Respir. J. 2012, 40:641-648.
37. Prednisone Behr J. azathioprine, and n-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012, 367:870-871.